close Icon

Research Articles

Explore our library of peer-reviewed publications below, with contributions from Burnet researchers.

See also: Research Reports + Policy Briefs

Form Loading Icon
Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry.

Liu X, Malins LR, Roche M, Sterjovski J, Duncan R, Garcia ML, Barnes NC, Anderson DA, Stone MJ, Gorry PR, Payne RJ

Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry.
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: meeting new challenges.

Kufareva I, Katritch V, Participants of GPCR Dock 2013, Stevens RC, Abagyan R

Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: meeting new challenges.
Lytic gene expression is frequent in HSV-1 latent infection and correlates with the engagement of a cell-intrinsic transcriptional response.

Ma JZ, Russell TA, Spelman T, Carbone FR, Tscharke DC

Lytic gene expression is frequent in HSV-1 latent infection and correlates with the engagement of a cell-intrinsic transcriptional response.
Reducing deaths from severe pneumonia in children in Malawi by improving delivery of pneumonia case management.

Enarson PM, Gie RP, Mwansambo CC, Maganga ER, Lombard CJ, Enarson DA, Graham SM

Reducing deaths from severe pneumonia in children in Malawi by improving delivery of pneumonia case management.
Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.

Moore BR, Benjamin JM, Salman S, Griffin S, Ginny E, Page-Sharp M, Robinson LJ, Siba P, Batty KT, Mueller I, Davis TM

Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.

Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Mårtensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guérin P, Davis TME, Ménard D, Adam I, Ademowo G, Arze C, Baliraine FN, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé AA, El-Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F, Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, Nzila A, Oguike M, Otienoburu SD, Ogutu B, Ouédraogo JB, Piola P, Rombo L, Schramm B, Somé AF, Thwing J, Ursing J, Wong RPM, Zeynudin A, Zongo I, Plowe CV, Sibley CH, Asaq Molecular Marker Study Group

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.